Participated · Series D · Mar 2026

Elite Robots develops a range of robotic products including collaborative robots, composite robots, and humanoid-like machines built on a core VLA+T architecture that fuses vision, language, action, and torque-optimized perception. The company emphasizes full-stack in-house capabilities from operating systems to joint modules, enabling integrated "hand, brain, eye, and foot" agent functionality. Its "one brain, multiple forms" strategy seeks to use a unified agent technology across multiple product form factors. Business performance is described as hyper-growth in group revenue, primarily driven by the composite robotics division, and the company is reported to be among the leaders in profitability in the intelligent robot core systems market. About half of its business relates to AI supply chain activities spanning optical modules, servers, smartphones, smart vehicles, and AI drug discovery. Elite Robots maintains dual headquarters in Suzhou and Zhengzhou and has expanded internationally into Europe, North America, and Southeast Asia with orders from several top-tier global clients.

Led · Equity · Oct 2025

Chando Group is a Chinese homegrown cosmetics brand that combines in-house raw material sourcing, research and development, and manufacturing with a fully digital operating system and efficient DTC distribution. The company manages multiple brands—including Chando, Perfection Research, Chunxia, Meisu, and Jichu—covering skincare, color cosmetics, personal care, men’s grooming, and baby care categories. Its R&D organization comprises 154 researchers with expertise spanning life sciences, material sciences, and applied chemistry. Chando has also partnered with medical institutions such as Huashan Hospital and the National Children’s Medical Center (Fudan University Children’s Hospital) to strengthen product innovation. The newly raised capital will be used to expand operations and support ongoing product development initiatives.

Led · Series B · Jul 2022

Syrius Robotics designs autonomous mobile robots (AMRs) that plan routes and react in real time to navigate narrow warehouse aisles and lift and put away parcels. The company positions itself more as a software firm, citing proprietary algorithms and an Android-based operating system it also licenses to third-party robot makers. Its revenue comes from selling robots, monthly robots-as-a-service subscriptions, and OS licensing; about half of revenues are from overseas markets. Syrius operates a subsidiary in Japan and counts Mitsubishi Corporation and Kantsu among its clients, and it also serves customers in Singapore and South Korea. The startup is looking to expand operations across Southeast Asia, North America, and Europe. Syrius employs around 200 people and told TechCrunch it is profitable, though it declined to disclose revenues.

Participated · Series C · Jun 2022

MegaRobo Technologies builds automation solutions for life sciences R&D, offering products that range from benchtop workflow automation to fully automated platforms for complex, large-system workflows. Its workflow automation integrates AI software, analytical instruments, hardware and consumables into a single system. The company’s products are adopted in multiple countries and are used in applications such as antibody selection, cell line development and molecular screening. MegaRobo has collaborated with partners including CELLada on high-throughput organoid cultivation and Agilent Technologies on integrated automation for synthetic biology and biopharmaceutical R&D. Led by CEO Daniel Huang, the company plans to continue investing in R&D, increase capacity and pursue global expansion. The article reports a major financing event that strengthens the company’s ability to execute on those plans. MegaRobo is a Chinese high-tech startup that applies artificial intelligence and robotics to life sciences and other sectors. The company describes itself as operating at the intersection of AI, robotics and life‑science applications. According to a company statement reported in the article, MegaRobo has raised $65 million in a funding round. The round was led by Hong Kong‑listed pharma giant WuXi AppTec, and other named participants include Matrix Partners and Sinovation. No operating metrics, valuation, or detailed use-of-proceeds were disclosed in the article. Meiga Robotics builds automated robotics and AI solutions tailored to life‑science applications including new‑drug R&D, gene engineering, and clinical diagnostics. The company has deployed dozens of automated systems and served nearly 100 life‑science customers, driving large efficiency gains: operation precision and repeatability improved by two orders of magnitude, throughput rose up to 100x in some workflows, and certain automated diagnostic workstations enabled daily nucleic‑acid testing capacity of 260,000 samples. Standard product offerings include fully automated reagent filling and dispensing systems (processing up to 900 ep tubes per hour, ~4 seconds per tube). During COVID‑19, Meiga’s automated nucleic‑acid workstations delivered ~20x throughput versus manual methods while reducing frontline infection risk. The company in 2024 launched the Meiga “Kunpeng Laboratory” sub‑brand to integrate robotics, AI and biology, and it has internally developed automated platforms for mammalian cell culture, phenotypic detection, gene editing, and high‑throughput drug screening. Meiga plans to expand its core business and continue R&D and construction of the Kunpeng Laboratory to strengthen its competitive moat in life‑science automation. The company was founded in June 2016 and is based in Beijing.

Participated · Series B · Feb 2021

Neurophth Therapeutics develops AAV-based gene therapies for ophthalmic diseases, including advanced investigational programs such as NR082 for ND4-LHON. Its AAV platform has been validated by data from an investigator-initiated retinal gene therapy study. NR082 has received orphan drug designation from both the U.S. FDA and the EMA. The company’s pipeline also includes programs for autosomal dominant optic atrophy, optic neuroprotection, vascular retinopathy and other preclinical candidates. Neurophth has subsidiaries in China (Wuhan, Shanghai and Suzhou) and the U.S. (San Diego, CA) and is led by founder, chairman and CEO Bin Li. The firm intends to use the new proceeds to accelerate clinical trials, enhance R&D capabilities and expand its pipeline. Neurophth Therapeutics develops gene therapies targeting ophthalmic diseases, with its lead investigational candidate NR082 (NFS-01, rAAV2-ND4) for ND4-mediated LHON. NR082 has orphan drug designation from the U.S. FDA and its IND for a Phase 1/2/3 trial was approved by China NMPA in March 2021, with the first patient dosed in June 2021. The company’s pipeline includes ND1-mediated LHON, autosomal dominant optic atrophy, optic neuroprotection (e.g., glaucoma), vascular retinopathy (e.g., diabetic retinopathy) and five other preclinical candidates. Neurophth has initiated scale-up of in-house manufacturing using single-use technologies at its Suzhou facilities to support future commercial demand. The company intends to use newly raised capital to accelerate growth, advance its lead LHON program ex-China, enrich its R&D pipeline through business development, and continue expanding its international-standard gene therapy manufacturing platform. Neurophth is a fully integrated genetic medicines company focused on AAV-delivered gene therapies for ocular diseases. Its lead investigational candidate is NR082 (rAAV2-ND4) for ND4-mediated Leber hereditary optic neuropathy (LHON), which received U.S. FDA orphan designation in Q3 2020. The company expects to advance NR082 toward IND submission and to initiate clinical trials in the first half of 2021. Neurophth is developing a pipeline of 10 gene therapy product candidates addressing both rare and common ocular diseases, including ND1-mediated LHON, autosomal dominant optic atrophy, glaucoma, and diabetic macular edema. It is building a commercially scalable GMP manufacturing facility in Suzhou and scaling up in-house manufacturing using single-use technologies, and plans to establish translational research centers. Headquartered in Wuhan with subsidiaries in Shanghai, Suzhou, and the US, Neurophth closed a Series A in early 2020 to initiate facility construction and accelerate nonclinical studies.